The U.S. Food and Drug Administration (FDA) has issued a safety communication warning that certain type 2 diabetes drugs, called dipeptidyl peptidase-4 (DPP-4) inhibitors, may lead to severe joint pain in patients taking them. Among the diabetes drugs named in the announcement are Merck’s Januvia (sitagliptin) and AstraZeneca and Bristol-Myers Squibb’s Onglyza (saxagliptin); as well as Incretin mimetic drugs containing linagliptin or alogliptin.
Januvia was approved by the ...
continue reading...